Functional signaling biases in G protein-coupled receptors: Game Theory and receptor dynamics.

Pharmacotherapeutic targeting of G protein-coupled receptors (GPCRs) is perhaps the most important field of drug design, as agents designed to control these receptors constitute more than half of the pharmacopeia. Initially GPCRs were considered to be unitary entities, possessing all of their potential functionality in their characteristic heptahelical core. Early models of the functional activity of GPCRs considered them to possess just a simple 'on' or 'off' status. Recent research however has allowed us to realize that GPCR functionality is dependent upon many other proteins outside of the heptahelical core, on the site of GPCR expression in a tissue or a microdomain in a cell, and, most importantly, on the formation of differential 'active' states preferentially coupled to specific signal transduction structures. The recognition of such signaling diversity has facilitated the ability to appreciate and identify ligands for GPCRs that demonstrate a bias towards one signaling form of a receptor to another. However while potentially increasing our ability for selective signal targeting, our approach to understanding the physiological ramifications of systemic signaling manipulation is underdeveloped. This explosion in the complexity of GPCR signaling is now becoming familiar territory to receptor biologists, yet the application of this knowledge to drug design is relatively limited. This review will attempt to outline potential pitfalls and unseen benefits of using signaling bias in therapeutic design as well as highlighting new applications such as Game Theory for uncovering new therapeutic applications for biased agonists.

[1]  R. Lefkowitz,et al.  Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. , 1993, Trends in pharmacological sciences.

[2]  Jiaquan Xu,et al.  Death in the United States, 2007. , 2009, NCHS data brief.

[3]  L. Luttrell,et al.  Beyond Desensitization: Physiological Relevance of Arrestin-Dependent Signaling , 2010, Pharmacological Reviews.

[4]  M. Böhm,et al.  Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. , 1993, Circulation.

[5]  Stuart Maudsley,et al.  Minimal Peroxide Exposure of Neuronal Cells Induces Multifaceted Adaptive Responses , 2010, PloS one.

[6]  Stuart Maudsley,et al.  The Origins of Diversity and Specificity in G Protein-Coupled Receptor Signaling , 2005, Journal of Pharmacology and Experimental Therapeutics.

[7]  Bruce S. McEwen,et al.  Allostasis and Allostatic Load , 2007 .

[8]  Adam J Pawson,et al.  Gonadotropin-Releasing Hormone Functionally Antagonizes Testosterone Activation of the Human Androgen Receptor in Prostate Cells through Focal Adhesion Complexes Involving Hic-5 , 2007, Neuroendocrinology.

[9]  J. Violin,et al.  β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection , 2007 .

[10]  S. W. Jones,et al.  Commentary: a plausible model. , 1999, The Journal of general physiology.

[11]  L. Kunkel,et al.  Syntrophin binds to an alternatively spliced exon of dystrophin , 1995, The Journal of cell biology.

[12]  Adam J Pawson,et al.  Proline-rich tyrosine kinase 2 mediates gonadotropin-releasing hormone signaling to a specific extracellularly regulated kinase-sensitive transcriptional locus in the luteinizing hormone beta-subunit gene. , 2007, Molecular endocrinology.

[13]  R. Mullins,et al.  β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2 , 2000, The Journal of cell biology.

[14]  K. Becker,et al.  Growth Factor Signals in Neural Cells , 2009, Journal of Biological Chemistry.

[15]  W. Koch,et al.  Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. , 2007, Trends in molecular medicine.

[16]  M. Mattson,et al.  Hormesis : a revolution in biology, toxicology and medicine , 2010 .

[17]  P. Leff,et al.  Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. , 1998, Molecular pharmacology.

[18]  R. Lefkowitz,et al.  Platelet-Derived Growth Factor Receptor Association with Na+/H+ Exchanger Regulatory Factor Potentiates Receptor Activity , 2000, Molecular and Cellular Biology.

[19]  C. Hague,et al.  Blood Pressure Is Regulated by an α1D-Adrenergic Receptor/Dystrophin Signalosome* , 2008, Journal of Biological Chemistry.

[20]  R. Lefkowitz,et al.  β-Arrestin Scaffolding of the ERK Cascade Enhances Cytosolic ERK Activity but Inhibits ERK-mediated Transcription following Angiotensin AT1a Receptor Stimulation* , 2002, The Journal of Biological Chemistry.

[21]  B. Kobilka,et al.  Myocyte Adrenoceptor Signaling Pathways , 2003, Science.

[22]  S. Shenolikar,et al.  The β2-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange , 1998, Nature.

[23]  G. Grassi,et al.  Sympathetic activation in congestive heart failure: evidence, consequences and therapeutic implications. , 2009, Current vascular pharmacology.

[24]  L. Luttrell Composition and function of G protein-coupled receptor signalsomes controlling mitogen-activated protein kinase activity , 2007, Journal of Molecular Neuroscience.

[25]  Arthur Christopoulos,et al.  Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.

[26]  L. Kunkel,et al.  Cloning of human basic A1, a distinct 59-kDa dystrophin-associated protein encoded on chromosome 8q23-24. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Lefkowitz,et al.  A β-Arrestin–Biased Agonist of the Parathyroid Hormone Receptor (PTH1R) Promotes Bone Formation Independent of G Protein Activation , 2009, Science Translational Medicine.

[28]  A. IJzerman,et al.  Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist‐specific G protein activation , 2004, British journal of pharmacology.

[29]  T. Kenakin Functional Selectivity and Biased Receptor Signaling , 2011, Journal of Pharmacology and Experimental Therapeutics.

[30]  T. Kohout,et al.  Targeting of Cyclic AMP Degradation to β2-Adrenergic Receptors by β-Arrestins , 2002, Science.

[31]  J. Cartaud,et al.  Identification of dystrophin-binding protein(s) in membranes from Torpedo electrocyte and rat muscle. , 1993, The Journal of biological chemistry.

[32]  T. Kenakin,et al.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. , 1995, Trends in pharmacological sciences.

[33]  A Karlin,et al.  On the application of "a plausible model" of allosteric proteins to the receptor for acetylcholine. , 1967, Journal of theoretical biology.

[34]  L. Luttrell,et al.  Transactivation of the epidermal growth factor receptor mediates parathyroid hormone and prostaglandin F2 alpha-stimulated mitogen-activated protein kinase activation in cultured transgenic murine osteoblasts. , 2003, Molecular endocrinology.

[35]  T. Kohout,et al.  Regulation of Receptor Fate by Ubiquitination of Activated β2-Adrenergic Receptor and β-Arrestin , 2001, Science.

[36]  R. Seifert,et al.  Differential coupling of the human cannabinoid receptors hCB1R and hCB2R to the G-protein Gαi2β1γ2 , 2008, Neuroscience Letters.

[37]  C. Christodoulou,et al.  Self-control with spiking and non-spiking neural networks playing games , 2010, Journal of Physiology-Paris.

[38]  Adam J Pawson,et al.  Gonadotropin-releasing Hormone-induced Activation of Diacylglycerol Kinase-ζ and Its Association with Active c-Src* , 2004, Journal of Biological Chemistry.

[39]  J. Wingfield,et al.  The concept of allostasis in biology and biomedicine , 2003, Hormones and Behavior.

[40]  T. Ebisawa,et al.  A novel scheme of dystrophin disruption for the progression of advanced heart failure. , 2005, Biochimica et biophysica acta.

[41]  J. Schaper,et al.  The Cytoskeleton and Related Proteins in the Human Failing Heart , 2000, Heart Failure Reviews.

[42]  R Seifert,et al.  Effects of guanine, inosine, and xanthine nucleotides on beta(2)-adrenergic receptor/G(s) interactions: evidence for multiple receptor conformations. , 1999, Molecular pharmacology.

[43]  Adam J Pawson,et al.  Gonadotropin-Releasing Hormone (GnRH) Antagonists Promote Proapoptotic Signaling in Peripheral Reproductive Tumor Cells by Activating a Gαi-Coupling State of the Type I GnRH Receptor , 2004, Cancer Research.

[44]  Xin Lin,et al.  β-Arrestin 2 is required for lysophosphatidic acid-induced NF-κB activation , 2008, Proceedings of the National Academy of Sciences.

[45]  C. Hague,et al.  Syntrophin isoforms play specific functional roles in the α1D-adrenergic receptor/DAPC signalosome. , 2011, Biochemical and biophysical research communications.

[46]  T. Sotnikova,et al.  An Akt/β-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and Behavior , 2005, Cell.

[47]  S. Liggett,et al.  Contribution of ligand structure to activation of alpha 2-adrenergic receptor subtype coupling to Gs. , 1994, Molecular pharmacology.

[48]  L. Luttrell Reviews in Molecular Biology and Biotechnology: Transmembrane Signaling by G Protein-Coupled Receptors , 2008, Molecular biotechnology.

[49]  B. Kobilka,et al.  Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations. , 2001, The Journal of pharmacology and experimental therapeutics.

[50]  G. Martin,et al.  Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. , 1998, The Journal of pharmacology and experimental therapeutics.

[51]  S. Maayani,et al.  Pleiotropic Behavior of 5‐HT2A and 5‐HT2C Receptor Agonists , 1998, Annals of the New York Academy of Sciences.

[52]  J. Finsterer,et al.  The Heart in Human Dystrophinopathies , 2003, Cardiology.

[53]  P. Tonali,et al.  γ1- and γ2-Syntrophins, Two Novel Dystrophin-binding Proteins Localized in Neuronal Cells* , 2000, The Journal of Biological Chemistry.

[54]  R. Lefkowitz,et al.  A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. , 1980, The Journal of biological chemistry.

[55]  W. Paulus,et al.  Myofilament dysfunction in cardiac disease from mice to men , 2008, Journal of Muscle Research and Cell Motility.

[56]  J. M. Smith,et al.  The Logic of Animal Conflict , 1973, Nature.

[57]  R. A. Hall,et al.  Fine-tuning of GPCR activity by receptor-interacting proteins , 2009, Nature Reviews Molecular Cell Biology.

[58]  Jyrki P. Kukkonen,et al.  Agonist trafficking of Gi/o‐mediated α2A‐adrenoceptor responses in HEL 92.1.7 cells , 2001 .

[59]  K. Flegal,et al.  Prevalence and trends in obesity among US adults, 1999-2008. , 2010, JAMA.

[60]  T. Kenakin Functional Selectivity through Protean and Biased Agonism: Who Steers the Ship? , 2007, Molecular Pharmacology.

[61]  L. Luttrell,et al.  G protein-coupled receptor signaling complexity in neuronal tissue: implications for novel therapeutics. , 2007, Current Alzheimer research.

[62]  Graeme Milligan,et al.  Identification of a serotonin/glutamate receptor complex implicated in psychosis , 2008, Nature.

[63]  Melanie G. Lee,et al.  RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor , 1998, Nature.

[64]  R. Lefkowitz,et al.  Targeting of Diacylglycerol Degradation to M1 Muscarinic Receptors by ß-Arrestins , 2007, Science.

[65]  R. Lefkowitz,et al.  Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor. , 1994, Molecular pharmacology.

[66]  S. Ferguson,et al.  Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. , 2001, Pharmacological reviews.

[67]  M. Caron,et al.  Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. , 1992, The Journal of biological chemistry.

[68]  Ted L. Anderson,et al.  On the Application of R -Curves and Maximum Load Toughness to Structures , 1988 .

[69]  M. Caron,et al.  Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. , 1999, Science.

[70]  L. Luttrell,et al.  ‘Biasing’ the parathyroid hormone receptor: A novel anabolic approach to increasing bone mass? , 2011, British journal of pharmacology.

[71]  M. F. Peters,et al.  Two forms of mouse syntrophin, a 58 kd dystrophin-associated protein, differ in primary structure and tissue distribution , 1993, Neuron.